Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.55 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | HTR1D | P28221 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | HTR1B | P28222 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414816 | 1.00 | HTR2C (0.55) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL7159098 | 0.87 | HTR2C (0.54) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL6469548 | 0.86 | HTR2C (0.60) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL23102845 | 0.85 | HTR2C (0.47) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL38656762 | 0.83 | HTR2C (0.50) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL7640404 | 0.83 | HTR2C (0.67) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL6978983 | 0.83 | HTR2C (0.54) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL8205708 | 0.83 | HTR2C (0.57) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL2494144 | 0.82 | HTR2C (0.52) | HTR2CHTR2AHTR1ACYP2D6HTR2B | |
| SCHEMBL15912345 | 0.79 | HTR1D (0.57) | HTR2CHTR2AHTR2BHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230124429-A1 | Highly Efficient Myeloperoxidase Activatable Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012174479-A1 | IN VIVO PROTEOMICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1347959-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
| EP-1268422-A1 | INDOLES FOR TREATING DISEASES THAT CAN BE TREATED USING THYROID HORMONES | Bayer Aktiengesellschaft (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002051805-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2001070687-A1 | INDOLES FOR TREATING DISEASES THAT CAN BE TREATED USING THYROID HORMONES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | HTR2C 2/4885HTR2A 1/4885HTR1A 4/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | HTR2C 1700/4885HTR2A 1348/4885HTR1A 1746/4885 |
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | HTR2C 14/4885HTR2A 11/4885HTR1A 17/4885 |
| US-20230124429-A1 | Highly Efficient Myeloperoxidase Activatable Imaging Agents | MPO, CAT, EPX | HTR2C 4409/4885HTR2A 4486/4885HTR1A 3718/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | HTR2C 1298/4885HTR2A 1526/4885HTR1A 2698/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | HTR2C 2231/4885HTR2A 1116/4885HTR1A 970/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | HTR2C 1836/4885HTR2A 1216/4885HTR1A 1556/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR2C 4731/4885HTR2A 4866/4885HTR1A 4710/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR2C 4731/4885HTR2A 4866/4885HTR1A 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.